… in psoriasis and psoriatic arthritis (… mTOR pathway in psoriasis and psoriatic arthritis-(i)
dysregulation of cytokines and growth factors in these inflammatory diseases activates the mTOR …

… Rapamycin, a mTOR inhibitor, has been used in few patients with psoriasis due to its
antiproliferative and immunosuppressive actions (75). Everolimus was also used successfully in a …

… Psoriatic arthritis (PsA) is a large volume of … 23 inhibitors, and janus kinase (JAK) inhibitors,
as well as those in development, such as RORγt inhibitors, anti-NGF agents, mTOR inhibitors …

… , we will address psoriatic arthritis and cardiovascular diseases. Psoriatic arthritis can occur
in … In a recent study, the mTOR inhibitor, rapamycin, was found to inhibit cell proliferation in …

… and the proliferative aspects of psoriatic disease [40,41,… mTOR inhibitors in psoriasis has
been encouraged by studies indicating the upregulation of PI3K/Akt/mTOR pathway in psoriatic …

… Regulatory T-cells from psoriasis patients show increased mTOR … both mTOR complexes
and thus inhibit Akt signaling, they could be interesting therapeutic compounds in psoriasis. …

… PI3K/Akt/mTOR pathway. In mice with IMQ-induced psoriasis, PSORI-CM02 relieved
psoriasis symptoms, induced autophagy and inhibited the phosphorylation of the PI3K/AKT/mTOR …

… mTOR and AKT. Induction of autophagy by mTOR inhibitor rapamycin and/or starvation also
inhibited … Herein, we also observed that inhibition of autophagy by IL-17A was accompanied …

… , M2 macrophages can also contribute to inflammation, for example by serving as hosts to
cytomegalovirus (CMV), which might explain the potent anti-CMV effects of mTOR inhibitors …

… dual PI3K/mTOR inhibitor, which possesses … psoriasis-like disease in Balb/c mice. Our
findings strongly suggest that therapeutic intervention with Del as a PI3K/mTOR kinase inhibitor …